Last reviewed · How we verify

NCT03514550

Effects of Anesthesia on Immunity in Cancer

Completed Phase 4 Last updated 3 June 2019
What this trial tests

Phase 4 trial testing Propofol in Surgery in 20 participants. Completed in 20 May 2019.

Timeline
14 May 2018
Primary endpoint
1 April 2019
20 May 2019

Quick facts

Lead sponsorMeshalkin Research Institute of Pathology of Circulation
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Enrollment20
Start date14 May 2018
Primary completion1 April 2019
Estimated completion20 May 2019
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Meshalkin Research Institute of Pathology of Circulation

Who can join

18 and older, any sex, with Surgery or Renal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is a comparative study of the cellular immunity response of patients operated on for kidney cancer under total intravenous and inhalational anesthesia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The immunosuppressive effects of volatile versus intravenous anesthesia combined with epidural analgesia on kidney cancer: a pilot randomized controlled trial.
    Efremov SM, Kozireva VS, Moroz GB, Abubakirov MN, et al · · 2020 · cited 6× · PMID 32098012 · DOI 10.4097/kja.19461

Verify or expand the search:

Other trials of Propofol

Trials testing the same drug.

Other recruiting trials for Surgery

Currently open trials in the same condition.

Other Meshalkin Research Institute of Pathology of Circulation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03514550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing